Solugen has 6 close competitors: Benchling, Signos, Abridge.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
SolugenBenchlingSignosAbridgeCMR SurgicalCommureBiomanufacturing technology company using engineered enzymes and metal catalysts to produce sustainable chemicals
Solugen competes with 6 companies here: Benchling, Signos, Abridge, Alloy Therapeutics, CMR Surgical, Commure.
Solugen was last valued at $2B (post-money, Mar 2026). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The routes section explains what is realistically available for a company at this stage.
No. Solugen is a private company; its shares do not trade on a public exchange.
The last valuation is $2B (post-money, Mar 2026).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
